Fresh analysis suggests that people who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain lost weight much more quickly than those who halt traditional lifestyle programs.
Published data in a major medical journal shows that while obese people often shed substantial amounts of their total mass while undergoing treatment, the weight returns at an average rate of nearly a kilo each month upon discontinuation.
"People buying such treatments need to be informed of the risk of fast weight regain when the medication is stopped," stated expert Dr. Susan Jebb.
This pace of regain implies a reversion to starting mass within about a year and a half.
Analyzing Treatments
The study, which reviewed dozens of trials involving over 9,000 of patients, compared the effects of the injectable medications with older methods.
The team note that people who lose weight through dieting usually experience a slower creep back—around 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Experts believe the way of the drugs explains the amplified weight return.
The injections mimic a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Long-term administration of GLP-1 levels several times higher than normal may cause the system to produce less of its endogenous GLP-1, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' leads to hunger is unsuppressed, making binge eating a significant risk."
A Chronic Condition?
The NHS advise the jabs for people with weight-linked medical conditions, alongside prescribed lifestyle changes.
Many experts argue that, given the likelihood of relapse, the treatment is often ongoing.
This opinion is reinforced by pharmaceutical companies, who state that the findings "highlight the chronic nature of excess weight," similar to managing diseases like hypertension.
Patient Accounts
Users who have come off the jabs describe a powerful resurgence of appetite.
"I experienced a trigger that goes on and I was suddenly starving," recalled an individual.
This challenge is exacerbated if users have not established sustainable lifestyle or habit changes during therapy.
Growing Adoption
Figures suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is higher among women compared to men.
- The 40s and 50s age group shows the greatest usage rates.
- Many obtain the drugs through private prescriptions rather than public health services.
In conclusion, researchers caution that while these medications are potent agents for shedding pounds, they are not a magic solution and maintained weight loss relies on integrated behavioural management.
